Method and composition for enhancement of male erectile function
View Patent ↗A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analog LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.
1. A method of enhancing male erectile function in a male having erectile dysfunction comprising administering to said male a composition comprising:
an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatomedin-C) and analogue LR3 IGF1; and
an androgen, in admixture with pharmaceutically acceptable diluents or carriers, wherein said composition is locally administered to the penis by injection or transdermal application and wherein the insulin-like growth factor is administered in the amount of 2-5 μg daily.
2. The method of claim 1 wherein said insulin-like growth factor is IGF-1.
3. The method of claim 1 wherein said insulin-like growth factor is LR3 IGF1.
4. The method of claim 1 wherein the transdermal application is in the form of patches, creams or lotions.
5. A method of enhancing male erectile function in a male having erectile dysfunction comprising administering to said male a composition comprising:
an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatomedin-C) and analogue LR3 IGF1; and
an androgen, in admixture with pharmaceutically acceptable diluents or carriers, wherein said composition is locally administered to the penis by injection or transdermal application and wherein the insulin-like growth factor is administered in the amount of 40-80 μg/kg, twice daily, up to a maximum of 120 μg/kg, twice daily.
6. The method of claim 5 wherein said insulin-like growth factor is IGF-1.
7. The method of claim 5 wherein said insulin-like growth factor is LR3 IGF1.
8. The method of claim 5 wherein the transdermal application is in the form of patches, creams or lotions.